Lithium and disease modification: A systematic review and meta-analysis in Alzheimer's and Parkinson's disease.
Ageing Res Rev
; 95: 102231, 2024 03.
Article
in En
| MEDLINE
| ID: mdl-38364914
ABSTRACT
The role of lithium as a possible therapeutic strategy for neurodegenerative diseases has generated scientific interest. We systematically reviewed and meta-analyzed pre-clinical and clinical studies that evidenced the neuroprotective effects of lithium in Alzheimer's (AD) and Parkinson's disease (PD). We followed the PRISMA guidelines and performed the systematic literature search using PubMed, EMBASE, Web of Science, and Cochrane Library. A total of 32 articles were identified. Twenty-nine studies were performed in animal models and 3 studies were performed on human samples of AD. A total of 17 preclinical studies were included in the meta-analysis. Our analysis showed that lithium treatment has neuroprotective effects in diseases. Lithium treatment reduced amyloid-ß and tau levels and significantly improved cognitive behavior in animal models of AD. Lithium increased the tyrosine hydroxylase levels and improved motor behavior in the PD model. Despite fewer clinical studies on these aspects, we evidenced the positive effects of lithium in AD patients. This study lends further support to the idea of lithium's therapeutic potential in neurodegenerative diseases.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Parkinson Disease
/
Neuroprotective Agents
/
Neurodegenerative Diseases
/
Alzheimer Disease
Limits:
Animals
/
Humans
Language:
En
Journal:
Ageing Res Rev
Journal subject:
GERIATRIA
Year:
2024
Document type:
Article
Country of publication:
Reino Unido